Glia as a new target for neuropathic pain, clinical proof of concept for palmitoylethanolamide, a glia-modulator

Anaesthesia, Pain and Intensive Care

Volumn 15, Issue 3, 2011, Pages 143-145

  Keppel Hesselink, Jan M ^a,b  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b Institute of Neuropathic Pain   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PALMIDROL; PLACEBO;

ABSENCE OF SIDE EFFECTS; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; EDITORIAL; GLIA; HUMAN; ISCHIALGIA; NEUROPATHIC PAIN; NONHUMAN; VISUAL ANALOG SCALE;

EID: 84857570737     PISSN: 16078322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Ohara PT, Vit JP, Bhargava A, Romero M, Sundberg C, Charles AC, Jasmin L.Gliopathic pain: when satellite glial cells go bad. Neuroscientist 2009;15(5):450-63
2. Desio,P et al. Efficacy of palmitoylethanolamide and oxycodon in patients with low back pain. Anesthesia and medicina critica (AMC) 2011;2:62-71
3. Desio P, Pregabalin and Palmitoylethanolamide in the treatment of neuropathic pain. Pathos 2010;117:9-14
4. Echeverry S, Shi XQ, Zhang J. Characterization of cell proliferation in rat spinal cord following peripheral nerve injury and the relationship with neuropathic pain. Pain 2008;135:3747
5. Saadé NE, Jabbur SJ. Nociceptive behavior in animal models for peripheral neuropathy: spinal and supraspinal mechanisms. Prog Neurobiol. 2008 Sep;86(1):22-47. Epub 2008 Jun 18
6. Muccioli GG, Stella N. Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology 2008;54(1):16-22. (Pubitemid 350299394)
7. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 2008;139(3):541-50.
8. De Filippis D, Luongo L, Cipriano M, Palazzo E, Cinelli MP, de Novellis V, Maione S, Iuvone T. Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol Pain 2011;7:3.
9. Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr, Carnuccio R, De Filippis D, Petrosino S, Iuvone T, Di Marzo V, Steardo L. Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. J Cell Mol Med. 2011 Jan 21. doi: 10.1111/j.1582-4934.2011.01267.x.
10. Keppel Hesselink, JM Syringomyelia in Cavalier spaniels treated succesfully with palmitoylethanolamide (Normast). http://www.neuropathie.nu/ research-development/syringomyelia-in-cavalier-spaniels-treated-succesfully- with-no.html
11. Guida, G, de Fabiani, A F. Lanaia, A. Alexandre, G.M. Vassallo, L. Cantieri, M. de Martino, M. Rogai, S. Petrosino La palmitoiletanolamida (Normast) en el dolor neuropatico cronico por lumbociatalgia de tipo compresivo: estudio clinico multicentrico. Dolor 2010;25:35-42.
12. Canteri L et al. Reduction of analgesics in patients suffering from lumbosciatic pain, treated with palmitoylethanolamide. Dolor 2010;25:227-234.
13. Keppel Hesselink JM. 2011 Overview all clinical trials with palmitoylethanolamide. http://www.chronicpaincoalition.com/1/24/502/normast- clinical-trial-overview. Accessed on
14. Hayashi Y, Kawaji K, Sun L, Zhang X, Koyano K, Yokoyama T, Kohsaka S, Inoue K, Nakanishi H. Microglial Ca2+-Activated K+ Channels Are Possible Molecular Targets for the Analgesic Effects of S-Ketamine on Neuropathic Pain. J Neurosci. 2011;31(48):17370-17382.